The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and ...

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Bank of America Corp DE reduced its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 72.1% ...

The study enrolled adults with platinum-resistant, FRα-expressing high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal ... when cancer cells stop responding to chemotherapy ...

Combination chemotherapy in platinum-resistant ovarian cancer eventually fails ... cancer of the fallopian tube and primary peritoneal cancer have a poor prognosis and a high rate of disease ...

Case study highlights how clinical operations teams can overcome complex regulatory and operational hurdles to finish a trial ...